Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Schöffski

Showing results (1-10 of 277) with videos related to

Pageof 28
Sort By:
The Oncologist|May 29, 2009
Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncologyPatrick Schöffski
Krankenpflege Journal|May 31, 2002
[Patient preference for oral chemotherapy]Patrick Schöffski
The Oncologist|September 12, 2020
Regarding "The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors"Patrick Schöffski
Oncology Research and Treatment|May 24, 2022
Established and Experimental Systemic Treatment Options for Advanced LiposarcomaPatrick Schöffski
Internal Medicine (Tokyo, Japan)|July 13, 2022
Complete Response to Eribulin in a Patient with Unresectable Liposarcoma: A Case Report and the Implications of New BiomarkersPatrick Schöffski
Anti-Cancer Drugs|April 13, 2004
The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumorsPatrick Schöffski
Expert Review of Anticancer Therapy|June 22, 2012
Pazopanib in the treatment of soft tissue sarcomaPatrick Schöffski
Oncology Research and Treatment|November 28, 2023
Current Role of Topoisomerase I Inhibitors for the Treatment of Mesenchymal Malignancies and Their Potential Future Use as Payload of Sarcoma-Specific Antibody-Drug ConjugatesPatrick Schöffski, Chao-Chi Wang, Morris Patrick Schöffski, et al.
Acta Oncologica (Stockholm, Sweden)|November 11, 2009
Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy managementPascal Wolter, Patrick Schöffski
Pharmacology & Therapeutics|January 14, 2020
Make your best BET: The emerging role of BET inhibitor treatment in malignant tumorsOliver Bechter, Patrick Schöffski
Pageof 28

Showing results (1-10 of 277) with videos related to

Sort By:
Pageof 28
The Oncologist|May 29, 2009
Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncologyPatrick Schöffski
Krankenpflege Journal|May 31, 2002
[Patient preference for oral chemotherapy]Patrick Schöffski
The Oncologist|September 12, 2020
Regarding "The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors"Patrick Schöffski
Oncology Research and Treatment|May 24, 2022
Established and Experimental Systemic Treatment Options for Advanced LiposarcomaPatrick Schöffski
Internal Medicine (Tokyo, Japan)|July 13, 2022
Complete Response to Eribulin in a Patient with Unresectable Liposarcoma: A Case Report and the Implications of New BiomarkersPatrick Schöffski
Anti-Cancer Drugs|April 13, 2004
The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumorsPatrick Schöffski
Expert Review of Anticancer Therapy|June 22, 2012
Pazopanib in the treatment of soft tissue sarcomaPatrick Schöffski
Oncology Research and Treatment|November 28, 2023
Current Role of Topoisomerase I Inhibitors for the Treatment of Mesenchymal Malignancies and Their Potential Future Use as Payload of Sarcoma-Specific Antibody-Drug ConjugatesPatrick Schöffski, Chao-Chi Wang, Morris Patrick Schöffski, et al.
Acta Oncologica (Stockholm, Sweden)|November 11, 2009
Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy managementPascal Wolter, Patrick Schöffski
Pharmacology & Therapeutics|January 14, 2020
Make your best BET: The emerging role of BET inhibitor treatment in malignant tumorsOliver Bechter, Patrick Schöffski
Pageof 28